Lonza to Expand Early Phase Manufacturing Capacity

Lonza to Expand Early Phase Manufacturing Capacity to Serve Small Molecules Market

Basel, Switzerland, 15 December 2011 - Lonza today announces the expansion of its early phase manufacturing capacity in Nansha, China. The extended capabilities and infrastructure successfully brought online this year will help Lonza continue to meet the growing demands of its global small molecule customers.

Lonza has been producing small molecules in China since 1996 and has nearly 10 years of experience as a custom manufacturing supplier in China. The Nansha site currently operates two small scale trains supplying clinical material, three large scale API trains for metric tons, and cGMP laboratories to meet gram-scale demands. The small scale capacity was increased in 2011 with a new cGMP kilo-lab and an additional small scale train that have already successfully provided material to support clinical trials for its customers.

The investments in kilogram-scale and small scale production capacity to our Nansha set-up in 2011, have allowed us to offer increased flexibility and to more quickly respond to customer needs for clinical material. These enhanced capabilities, along with existing R&D and QA/QC expertise, will help Lonza to comprehensively address its customers' small molecules manufacturing needs.

"This investment speeds our efforts to establish the Lonza Nansha site as a standard of quality to serve our global customer base for all material needs from gram-scale to metric tons," said Stefan Stoffel, Head of Lonza's Chemical Manufacturing Business Unit. "With this expansion, Lonza's FDA approved Nansha site now offers a fully integrated end-to-end development and manufacturing solution for small molecules."

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

Further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
[email protected]

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
[email protected]

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
[email protected]